Goldman Sachs Group Inc Immunity Bio, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,288,907 shares of IBRX stock, worth $5.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,288,907
Previous 1,024,975 25.75%
Holding current value
$5.79 Million
Previous $6.48 Million 26.18%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.32 - $6.7 $876,254 - $1.77 Million
263,932 Added 25.75%
1,288,907 $4.78 Million
Q2 2024

Aug 13, 2024
SELL
$4.82 - $9.15 $917,756 - $1.74 Million
-190,406 Reduced 15.67%
1,024,975 $6.48 Million
Q1 2024

May 15, 2024
SELL
$3.23 - $6.17 $204,320 - $390,295
-63,257 Reduced 4.95%
1,215,381 $6.53 Million
Q4 2023

Feb 13, 2024
BUY
$1.25 - $5.21 $1.06 Million - $4.43 Million
850,874 Added 198.91%
1,278,638 $6.42 Million
Q3 2023

May 14, 2024
SELL
$1.29 - $3.1 $1.1 Million - $2.64 Million
-850,874 Reduced 66.55%
427,764 $722,000
Q3 2023

Nov 14, 2023
BUY
$1.29 - $3.1 $199,490 - $479,396
154,644 Added 56.62%
427,764 $722,000
Q2 2023

May 14, 2024
SELL
$1.53 - $6.41 $123,074 - $515,626
-80,441 Reduced 22.75%
273,120 $759,000
Q2 2023

Aug 14, 2023
SELL
$1.53 - $6.41 $123,074 - $515,626
-80,441 Reduced 22.75%
273,120 $759,000
Q1 2023

May 14, 2024
SELL
$1.35 - $4.78 $1.08 Million - $3.82 Million
-798,163 Reduced 69.3%
353,561 $643,000
Q1 2023

May 11, 2023
SELL
$1.35 - $4.78 $1.08 Million - $3.82 Million
-798,163 Reduced 69.3%
353,561 $643,000
Q4 2022

May 14, 2024
BUY
$4.35 - $6.77 $2.55 Million - $3.97 Million
585,881 Added 103.54%
1,151,724 $5.84 Million
Q4 2022

Feb 13, 2023
BUY
$4.35 - $6.77 $2.55 Million - $3.97 Million
585,881 Added 103.54%
1,151,724 $5.84 Million
Q3 2022

May 14, 2024
SELL
$3.65 - $6.43 $18,239 - $32,130
-4,997 Reduced 0.88%
565,843 $2.81 Million
Q3 2022

Nov 10, 2022
SELL
$3.65 - $6.43 $18,239 - $32,130
-4,997 Reduced 0.88%
565,843 $2.81 Million
Q2 2022

May 14, 2024
SELL
$2.68 - $6.14 $1.9 Million - $4.35 Million
-707,798 Reduced 55.36%
570,840 $2.12 Million
Q2 2022

Aug 15, 2022
BUY
$2.68 - $6.14 $435,942 - $998,763
162,665 Added 39.85%
570,840 $2.12 Million
Q1 2022

May 16, 2022
BUY
$5.05 - $7.53 $739,703 - $1.1 Million
146,476 Added 55.97%
408,175 $2.29 Million
Q4 2021

Feb 14, 2022
BUY
$5.67 - $10.18 $203,847 - $365,991
35,952 Added 15.93%
261,699 $1.59 Million
Q3 2021

Nov 10, 2021
BUY
$9.17 - $14.24 $2.07 Million - $3.21 Million
225,747 New
225,747 $2.2 Million

Others Institutions Holding IBRX

# of Institutions
202
Shares Held
70M
Call Options Held
1.68M
Put Options Held
1.31M
View Full List

About ImmunityBio, Inc.

IBRX Quotes by TradingView
  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email